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Elevation of albumin synthesis rates in nephrotlc patients measured
with [1-'3C]leucine. Eight patients with a nephrotic syndrome and a
histologically-proven kidney disease were compared to age- and sex-
matched healthy volunteers. Albumin synthesis rates were measured
after injection of '3C-labelled leucine (57 mg/kg body wt, 19.4 atoms%).
Plasma volume was determined with '25I-albumin. The fractional syn-
thesis rate of albumin was 7.9 0.4%/day in control subjects in
comparison with a marked elevation to 18.4 2.0%/day (P < 0.001) in
nephrotie patients. The absolute synthesis rate was 145 9 mg/kg/day
in control subjects compared with 213 17 mg/kg/day (P = 0.005) in the
nephrotic patients. There was a statistically significant correlation
between ASR and urinary albumin loss (P = 0.035) and serum choles-
terol concentration (P = 0.007). The calculated oncotic pressure was
significantly lower in the nephrotic group than in the controls (P <
0.001), but was without correlation with ASR.
The nephrotic syndrome (NS) is characterized by an in-
creased permeability of the glomerular filter with urinary loss of
protein, in particular albumin, resulting in hypoalbuminemia,
hypoproteinemia, and dysproteinemia. Determination of albu-
min metabolism in vivo by measurement of the decay of
radio-iodinated albumin led Jensen et alto report a series of 30
patients with nephrotic syndrome: however, he and several
other authors could not elucidate the question whether syn-
thetic rates of albumin are markedly elevated in the nephrotic
syndrome compared with healthy subjects [1—3]. More recent
studies have focused on possible nutritional intervention in the
nephrotic syndrome [4]. This is of particular interest as the
formerly recommended diets, high in protein content, have
been criticized because renal function seems to deteriorate
more rapidly with such regimens [5, 6]. Although a higher rate
of albumin synthesis was demonstrated in nephrotie patients on
a higher protein diet, no clear elevation was demonstrated in
comparison with healthy subjects, as no normal controls were
included in the study [4, 7].
The main hurdle for investigating these questions is that the
commonly used methods for measuring albumin synthesis rates
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are inconvenient and potentially hazardous for the patient,
because a radioactive tracer is needed. We have therefore
developed a new method for measuring albumin synthesis rates
employing stable isotopes, which is both safe and easily prac-
ticable [8]. The method has proved to be reproducible and
reliable in healthy volunteers and is ideal for clinical investiga-
tions, because the time period required for measuring albumin
synthesis is shortened to a minimum of 90 minutes. As a
consequence we have applied this method to compare rates of
synthesis of albumin in patients with the nephrotic syndrome to
rates in healthy volunteers who were matched for sex, age and
dietary protein intake.
Methods
Patients
Eight male patients (46 4 years, 82 3 kg) with an
established history of a nephrotic syndrome and a recent renal
biopsy were selected from the Renal Unit of the Aberdeen
Royal Infirmary.
The details of the participants of the study are summarized in
Table 1. Patient 8 was not nephrotic by definition at the time of
the experiment. He was in partial remission, but excreted far
more albumin than normal, and was therefore included. Seven
patients had a glomerulonephritis (UN) (4 membranous UN, 1
membrano-proliferative UN, 2 minimal change UN) and one
patient had a primary amyloidosis. Although amyloidosis com-
monly affects the liver, this patient showed no signs of a
compromised liver metabolism, since liver enzymes (AAT 21
U/liter, GUT 22 U/liter, bilirubin S .tmol/liter, alkaline phos-
phatase 77 U/liter) and hepatic coagulation factors (fibrinogen
3.4 g/liter, prothrombin time 14 see) were normal. Patients 1, 2,
4, 5, 7 and 8 were under diuretic treatment until three days prior
to the experiment. Patient S was under drug therapy with
cyelosporine (300 mg/day) for his renal disease and had a serum
concentration of cyclosporine within the therapeutic range.
Patient 2 was antieoagulated because of a history of recurrent
pulmonary embolism in the last three years. A high blood
pressure had been successfully treated in patients 1 and 2 (with
diuretics and beta-blockers) for more than one year. Five
patients indicated a slight to moderate impairment of renal
function with a ereatinine clearance between 50 and 78 mllmin.
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Table 1. Characteristics of control subjects and patients with
nephrotic syndrome
Patient No.
Age
years
Serum Serum
Weight albumin protein
kg gluier
Urinary Urinary
albumin protein
giday
Control
1
2
3
4
5
6
7
Mean±5EM
44
35
49
58
38
29
52
44±4
66
76
88
74
90
77
85
79±3
45 70
41 59
47 70
39 57
46 66
48 67
44 72
44±1 66±2
— —
— —
— —
— —
— —
— —
— —
— —
Nephrotic
1
2
3
4
5
6
7
8
Mean SEM
42
37
54
66
42
35
51
4046 4
72
72
71
91
90
94
84
8582 3
28 51
32 52
24 47
23 46
30 55
32 48
31 59
35 68
29 2° 53 3b
7.5 9.9
2.1 3.3
3.8 12.0
7.8 12.0
4.3 6.0
4.6 6.6
4.2 7.1
0.8 1.5
44 0.8 7.3 1.4
a P < 0.001 vs. controlb P = 0.003 vs. control
Immunoelectrophoresis of patient 7 revealed a paraprotein of
the lambda type, but the bone marrow aspiration was not
indicative of a neoplastic process.
A group of seven healthy male volunteers was selected from
the Rowett Institute staff and matched as close as possible in
regard to age, weight, height and habitus. The mean age was 44
4 years and the body weight, at the morning of the experi-
ment, was 79 3 kg. As indicators of a normal hepatic function
and cellular integrity of the liver, plasma fibrinogen, prothrom-
bin time, liver enzymes (aspartate amino transferase and gam-
ma-glutamyl transferase), bilirubin and alkaline phosphatase
were measured in volunteers and patients. All values were
within the normal range except for patient S and volunteer 7,
who showed unexplained slight elevations of alkaline phos-
phatase (126 U/liter and 118 U/liter respectively; normal value
<105 U/liter).
All participants received a standard diet during the three days
prior to the investigation, providing 1 g of protein per kg body
weight per day, 89 g fat and 274 g of carbohydrates per 70 kg
body weight (energy content equals 1.4 times estimated basal
metabolic rate). Written informed consent was obtained from
each subject. The study protocol was approved by the Joint
Ethical Committee of the Grampian Health Board.
Experimental procedures
Albumin synthesis rates were measured by rapid injection of
a large dose of an isotopically-labelled amino acid [8]. The aim
of the large (or "flooding") dose is to equilibrate the isotopic
enrichment of the free amino acid in serum with that in the liver
tissue. This approach minimizes uncertainty about the isotopic
enrichment of the direct hepatic precursor pool of albumin
synthesis. We have previously demonstrated [8] the similarity
of the isotopic enrichment in liver relative to serum by mea-
surements on operative liver biopsies.
The subjects were fasted overnight before the experiment and
were in a supine position for 30 minutes prior to and throughout
the experiment. At 09:00 L-(1 13C)leucine (57 mg/kg body wt,
19.4 atoms%, Tracer Technologies, Somerville, Massachusetts,
USA), dissolved in 0.45% saline solution (200 mlI7O kg body wt)
and sterilized by filtration through a 0.22 tm pore single use
filter (Millipore, Molsheim, France) was injected over 10 min-
utes via a cubital cannula. Blood samples were taken from the
opposite cubital vein at intervals up to 90 minutes. At 30
minutes after the start of the procedure 0.070 to 0.080 MBeq
(that is, about 2 MCi) of 1251-albumin (Amersham, Bucks, UK)
was injected to measure plasma volume and to estimate the
transcapillary escape rate (TER) of albumin [9]. Unfortunately,
plasma volume could not be measured using the non-radioac-
tive Evans Blue, since this was recently withdrawn from the
market because of a potential carcinogenic effect. Samples for
counting were drawn at 10, 20 and 60 minutes after injecting
albumin. Iodine uptake by the thyroid gland was blocked by
oral potassium iodide (60 mg/day) starting the day before the
measurement. Plasma volume could not be determined in
volunteers 6 and 7 and in patient 7, so it was estimated from a
normogram [10].
A blood sample for determination of the clinical laboratory
values was drawn at zero time-point and a 24-hour urine
collection preceded the experiment for determination of albu-
min and protein excretion.
Determination of'3C-enrichment of leucine from albumin and
of plasma free leucine
The method has been described in detail elsewhere [8].
Briefly, serum albumin was separated from 10% trichloroacetic
acid precipitated serum proteins by differential solubility in
ethanol. Purity of the isolated albumin of control and nephrotic
subjects was checked by SDS-gel electrophoresis using a nor-
mal human serum albumin as standard. After washing with 2%
perchloric acid, albumin was hydrolyzed in 6 M HCI for 24
hours at 105°C. Leucine was then separated by ion exchange
chromatography (Locarte, UK; 60 x 0.9 cm column). The
column eluate containing the leucine was desalted by ion
exchange (5 ml of Resin AG 50W-x8, Bio-Rad Laboratories,
Richmond, California, USA) and dissolved in 0.1 M HCI. The
'3C-enrichment of the 13C02 was determined after decarboxy-
lation of the leucine with ninhydrin (Sigma, Poole, Dorset, UK)
on a gas isotope ratio-mass spectrometer (SIRA 12, VG Isogas,
Manchester, UK). The isotopic enrichment of serum free
leucine was measured as the tertiary butyldimethylsilyl deriva-
tive [11] by gas chromatography-mass spectrometry on a VG
12-250 quadrupole mass spectrometer (VG Masslab, Manches-
ter, UK).
Calculation of albumin synthesis rates
Albumin synthesis was expressed as the fractional synthesis
rate (FSR; that is, the percentage of the intravascular albumin
pool synthesized per day) and was calculated by dividing the
(13C)leucine enrichment of albumin by the area under the curve
of the precursor enrichment [8].
FSR was calculated from the equation:
FSR = (P2—P1) x 100/A
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Fig. 1. Enrichment of leucine in albumin after
injecting a flooding dose of f'3CJleucine. A.
Control subjects. B. Nephrotic patients. After
a lag period of about 35 minutes the
[13Clleucine enrichment in albumin increases
almost linearly up to 90 minutes. The
90 difference in ['3C]leucine enrichment at 70 and
90 minutes reflects the increase in albumin
synthesis rates in nephrotic patients.
where P2 represents the isotopic enrichment of leucine in
albumin at the end-point of the measurement (90 mm) and P1 at
the beginning of the linear increase of albumin enrichment (50
rain) in Figure 1. The area under the curve for precursor
enrichment A was determined by summation of the areas
between successive measurement points on the curve of the
enrichment of serum free leucine versus time (Fig. 2). The
appropriate section of the curve of precursor enrichment was
determined by subtracting 1 secretion time (ST), because the
albumin appearing at a time corresponding to P1 was in fact
synthesized 1 ST earlier. Complete details have been given
previously [8].
Albumin synthesis was also expressed as the total amount of
albumin synthesized per day. From plasma volume and plasma
albumin concentration the intravascular albumin mass (JAM)
was calculated, and this value was multiplied by the FSR to give
the absolute rate of albumin synthesis (ASR), expressed in
g/day or mg/kg body weight per day.
Oncotic pressure was calculated by the formula of Keys [12]
taking into account the plasma concentration of albumin and
total globulins.
Clinical laboratory values
Biochemical measurements (serum albumin, protein, liver
enzymes) were performed on a Technicon RA-l000/SMAC 11
automated analyzer (Technicon Instruments, Corp., Tarry-
town, New York, USA) except serum electrophoresis which
was determined on a Beckman Paragon System (Beckman
Instruments, Inc., Brea, California, USA).
Estimate of transcapillary escape rate (TER) of albumin
Assuming even distribution of '251-albumin by 20 minutes
after injection, the decrease of plasma radioactivity up to 90
minutes reflects the loss of albumin from the intravascular
space. An estimate of TER was calculated from the fall in
1251-albumin content of the plasma between 20 and 60 minutes,
assuming a linear fall, and is expressed as percent per hour.
Statistics
Data are presented as mean values SEM. The differences
between the two groups were assessed by the Student's f-test.
The relation between absolute albumin synthesis rates and
urinary albumin loss (and serum cholesterol) was calculated as
a linear correlation.
Results
In Table 2 albumin synthesis rates for all subjects are
summarized. The FSR of albumin was more than twofold higher
in the nephrotic patients than in the control subjects (P <
0.001). However, the serum albumin concentration and the
intravascular albumin mass were lower in the nephrotic indi-
viduals. Thus, the absolute synthesis rates were only 40%
A 1.20
1.15
1.10
1.05
B 1.20
1.15
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Fig. 2. Isotopic enrichment of serum free
leucine. A. Control subjects. B. Nephrotic
patients. After a large i.v. dose of
['C]leucine, the enrichment increases rapidly
and falls slowly and steadily thereafter.
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FSR
%/day
ASR
g/day
ASR
mg/kg/day
Control
1 5.8 40 2805 126 7.3 111
2 8.1 40 3132 128 10.4 137
3 9.1 36 3524 166 15.1 171
4 8.1 37 3130 122 9.9 134
5 8.0 37 3383 156 12.5 139
6 8.5 38 3504 168 14.3 186
7 7.5 38 3540 156 11.7 137
Mean SEM 7.9 0.4 38 1 3288 104 146 7 11.6 1.0 145 9
Nephrotic
1 19.8 33 3371 94 18.7 261
2 12.8 37 3276 105 13.4 186
3 20.7 36 3051 73 15.1 214
4 28.8 43 3593 83 23.8 261
5 15.3 36 3127 94 14.4 160
6 18.7 40 2972 95 17.8 190
7 21.3 33 3494 108 23.1 275
8 10.1 36 3692 129 13.1 155
Mean SEM 18.4 2.Oa 36 1 3322 92 89 6 18.0 1.6' 213 17C
Abbreviations are: FSR, fractional synthesis rate of albumin; ST, secretion time; PV, plasma volUme; 1AM, intravascular albumin mass; ASR,
absolute synthesis rate of albumin.
a <o.ooi
b P = 0.008
P = 0.005
higher (P = 0.005) in the patients with NS. Urinary protein loss
in the nephrotic group ranged from 1.5 to 12.0 g/day and urinary
albumin from 0.8 to 7.8 g/day.
Figure 1 illustrates the 13C-enrichment of leucine in albumin
over the incorporation time of 90 minutes. After a lag period of
30 to 40 minutes, that is, the secretion time, the '3C-enrichment
started to rise and soon followed a nearly linear increase until
the end of the observation period. The secretion time has been
shown to be constant in animals [13], and the method allows us
to estimate this parameter for the first time in humans [8]. There
is no significant difference in the secretion time between control
and nephrotic subjects, confirming the fact that the secretion
time is constant [8, 13].
Figure 2 illustrates the time course of the '3C-enrichment of
serum free leucine. By the injection of a large dose of [3CI1eu-
cine, a rapid increase in serum free leucine enrichment was
achieved, with a peak value at 10 minutes. Thereafter a slow
and steady fall in enrichment occurred over the subsequent 90
minutes. Serum free leucine reflected the precursor pool for
albumin synthesis [8], and it was important to know that its
enrichment was reasonably constant over the time period where
albumin synthesis rates were measured, to allow the determi-
nation of secretion time by back extrapolation of the linear part
of the protein enrichment curve. As Figure 2 shows, the fall in
enrichment was only substantial after 50 minutes. However, the
relevant area under the precursor curve for the calculation of
albumin synthesis rates was shifted one secretion time to the
left relative to the curve for albumin enrichment, because
albumin molecules appearing at 50 minutes were synthesized
one secretion time (about 37 mm) earlier. Therefore, the decline
of the enrichment of the precursor pool after 50 minutes did not
affect the accuracy of the measurement.
In Figure 3 absolute synthesis rates of albumin in NS patients
are plotted against urinary albumin loss, both expressed as mg
per kg body weight per day. Including all patients the correla-
tion was significant (r = 0.7423) with P = 0.035. The gradient of
the regression line is 1.18 0.44. It is noteworthy that the
intercept on the ASR axis is 150 mg/kg/day, which is precisely
the mean value for ASR of the control subjects, who were not
included in the correlation. The two values which deviated from
Table 2. Albumin synthesis rates of volunteers and nephrotic patients
ST PV 1AM
mm ml g
300
250
200
E
ci)
at
150
100
Urinary albumin, mg/kg/day
Fig. 3. Correlation between the absolute rate of albumin synthesis and
urinary albumin loss in nephrotic patients (r = 0.7423, P = 0.035).
0 20 40 60 80 100 120
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the regression line correspond to the patients with cyclosporin
and the paraprotein.
Oncotic pressure has been discussed as a possible factor
influencing albumin synthesis [14, 15]. We have calculated
colloid-osmotic pressure from serum albumin concentration
and total globulin concentration according to the formula of
Keys [12]. Oncotic pressure was 16 1 mm Hg in patients with
nephrotic syndrome compared to 23 1 mm Hg in control
subjects (P < 0.001), but there was no correlation between
absolute synthesis rates and oncotic pressure (P 0.2). The
correlation between ASR and serum albumin concentration was
not significant either (P = 0.15).
Serum cholesterol concentration was 6.0 0.5 mmollliter in
controls (range 5.2 to 8.9) and 9.7 0.9 (range: 6.1-13.7) in
nephrotics (p = 0.004). Serum triglyceride levels were not
significantly different between control and nephrotic subjects
(1.4 0.2 mmol/liter vs. 2.8 0.8). The correlation between
serum cholesterol concentrations and absolute rates of albumin
synthesis was statistically significant (r 0.8534, P 0.007),
but for triglycerides and albumin there was no significant
correlation. Urinary albumin losses showed a positive correla-
tion (r = 0.7729, P = 0.025) with serum cholesterol [161.
Nephrotic patients showed a moderate increase of TER to
8%/hr (range 5 to 1 3%/hr) compared with controls (4%/hr, range
1 to 7%/hr, P = 0.02).
Discussion
This study clearly demonstrates that rates of albumin synthe-
sis in nephrotic patients are elevated in comparison with those
in healthy subjects. Previous studies have been inconclusive
because inconsistent groups were selected and the method
used, decay of radio-iodinated albumin, was inconvenient,
requiring long periods of measurement and a relatively large
dose of radiation. More recent, direct methods for determina-
tion of albumin synthesis in humans have used the incorpora-
tion of '4C from carbonate into albumin [17, 18] or the admin-
istration of stable isotopes, for example, intravenous [19] or
oral ('5N)glycine [20]. These methods might also not be ideal.
The time period for measuring albumin synthesis, although
much shorter than with '2I-albumin, is still inconveniently
long, up to 72 hours [19]. Moreover, it is also important to
assess the labelling of the precursor pool for albumin synthesis,
and this cannot be achieved with certainty, because different
enrichments of the labelled amino acids occur in different body
compartments [211. Our recently developed method for mea-
suring albumin synthesis [8] is derived from the "flooding (or
large) dose technique" [21, 22] which has been widely used for
assessing rates of protein synthesis in cultured cells [23],
isolated tissues in vitro [24, 25], tissues of experimental animals
in vivo [22, 261, and muscle in human volunteers [21]. This
approach seeks to avoid most of the problems arising from
intracellular compartmentation, because uniform isotopic en-
richment of the precursor pool for albumin synthesis is ensured
by injecting a large dose of labelled leucine. Furthermore, the
time period of measurement is only 90 minutes, which is
convenient for both the patient and the investigator. In addi-
tion, the time period over which albumin synthesis is calculated
is reduced to 40 minutes, thus avoiding potential errors from
transcapillary escape of labelled albumin molecules, which is
very small during this tithe, even in the nephrotic group who
exhibited a slight increase in TER. The reproducibility of FSR
and ASR in the same subject is good [8], and the need for
radioactive tracers is restricted to a very small amount of
'251-albumin for determination of TER and plasma volume.
Both FSR and ASR of albumin were markedly elevated in the
nephrotic syndrome. Although this might appear to contradict
results of Kaysen et al, who obtained normal synthesis rates in
patients with the nephrotic sytnlrome [4], they were relating
results in nephrotic patients to healthy control from a previous
study [7]. However, our findings are well in accordance with
data from nephrotic rats, where an increase of ASR from 10 to
22 mg/hr/lOU g body weight was shown [27]. Moreover, as
Figure 3 demonstrates, there is a significant correlation between
albumin synthesis rates and urinary albumin loss. A similar
correlation has been reported previously, but only by including
each patient twice, once while on a high protein diet (1.6 g/kg
body wt) and again on a low protein diet (0.8 g/kg body wt). The
higher protein intake increased both albumin synthesis and
excretion resulting in a significant correlation, even though the
relationship does not appear to be significant when only those
on either fixed intake are included [7]. In the present study all
the subjects received 1.0 g/kg body wt dietary protein and the
correlation was significant. The gradient of the regression line is
not significantly different from unity. Although this slope of
unity might seem to imply full compensation for urinary losses
through an increase in synthesis, this is unlikely, since it would
then be difficult to explain the reduced serum albumin concen-
trations. An alternative explanation is that albumin degradation
might have been increased, since there is known to be a
substantial degradation of albumin in the renal tubule [28].
However, it is not possible to distinguish between these alter-
natives, as degradation was not measured and the estimate of
the slope of the regression line has wide confidence levels.
The other factors regulating albumin synthesis are not well
known. Serum albumin concentration itself does not seem to
have a regulatory effect [15], as is also suggested by the lack of
correlation between the ASR and concentration of albumin in
the present study, but oncotic pressure has been often dis-
cussed as a potential factor. Although we found a significant
decrease in the calculated values for oncotic pressure [12] in
nephrotic patients, there was no correlation with albumin
synthesis rates. In experimental healthy animals, several con-
ditions associated with an increased plasma oncotic pressure,
for example, hypergamma-globulinemia [29, 30], reduced the
rate of albumin synthesis. Moreover, alterations of the extra-
cellular oncotic pressure had a regulatory effect on albumin
mRNA in cultured rat hepatoma cells [31] and in vivo [321.
However, in work on hepatocytes, where oncotic pressure was
measured directly, no regulatory effect on albumin synthesis
was found [15]. It is also possible that in humans, in particular
those with a disease which affects plasma protein metabolism,
regulation of albumin synthesis might be different and indepen-
dent from oncotic pressure.
The mechanism of regulation of albumin synthesis within the
hepatocyte is slightly better known [33, 34]. After synthesis by
the ribosome the albumin molecule is transported through the
liver cell and is then secreted into the blood stream. The time
required for ribosomal synthesis and transport of albumin
through the hepatocyte is known as the secretion time [13]. In
rats the secretion time has been shown to be 15 to 20 minutes
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[13], but no values have been available for humans because the
methods for measuring albumin synthesis did not allow the
estimation of secretion time. However, it can be estimated with
the present technique in humans [8] from the intersection of the
linear increase in isotopic enrichment of albumin with the
zero-time enrichment (Fig. 1). It is a rather constant time
interval of 30 to 40 minutes in healthy subjects 18]. There was no
difference in secretion time between healthy and nephrotic
subjects in the present study. This confirms that secretion time
is, indeed, a fixed time interval in humans, irrespective of the
actual amount of albumin being synthesized. This suggests in
humans that the regulation of albumin synthesis does not occur
at the processing and secretion stage.
Kaysen et a! have previously reported a positive correlation
of ASR with serum cholesterol but have again included each
patient twice, on different dietary protein regimens [see above,
7, 35]. If the data are analyzed for either group separately the
correlation seems not to be significant. We showed in the
present study that a significant correlation was obtained in a
consistent group of nephrotic patients on the same dietary
regimen. However, this correlation should not be taken to
imply causality, and it is likely that increased albumin synthesis
and increased serum cholesterol are independent consequences
of the nephrotic syndrome.
In sumnary, we have shown for the first time that patients
with the nephrotic syndrome have a markedly-elevated albumin
synthesis rate compared with well-selected healthy volunteers.
Measurement of albumin synthesis rates by the flooding dose
technique employing stable isotopes is a promising approach in
the clinical environment. It is reproducible and convenient, and
could yield a major contribution to the investigation of the acute
and chronic regulation of albumin synthesis in different clinical
conditions.
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